- Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) gained 17.3% after the specialty pharmaceutical company received the FDA approval for EXSERVAN for the treatment of amyotrphic lateral sclerosis.
- Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rose 8.4% after the FDA accepted Intercept’s New Drug Application for obeticholic acid for the treatment of Liver Fibrosis.
- Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) declined 76% after the clinical-stage biopharmaceutical company halted the clinical development of Seladelpar.
- Shares of Surface Oncology, Inc. (NASDAQ:SURF) lost 21% after clinical-stage immuno-oncology company reported a $25 million debt financing from K2 HealthVentures.
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
CymaBay Therapeutics Inc. (CBAY): Free Stock Analysis Report
Surface Oncology, Inc. (SURF): Free Stock Analysis Report
Aquestive Therapeutics, Inc. (AQST): Free Stock Analysis Report
Original post
Zacks Investment Research